Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated